Abstract: Incidence of cardiovascular (CV) and metabolic disease is increasing, in parallel with associated risk factors. These factors, such as low-density lipoprotein (LDL)-cholesterol, elevated blood pressure, obesity, and insulin resistance have a continuous, progressive impact on total CV risk, with higher levels and numbers of factors translating into greater risk. Evaluation of all known modifi able risk factors, to provide a detailed total CV disease (CVD) and metabolic risk-status profi le is therefore necessary to ensure appropriate treatment of each factor within the context of a multifactorial, global approach to prevention of CVD and metabolic disease. Effective and well-tolerated pharmacotherapies are available for the treatment of risk-factors. Realization of the potential health and economic benefi ts of effective risk factor management requires improved risk factor screening, early and aggressive treatment, improved public health support (ie, education and guidelines), and appropriate therapeutic interventions based on current guidelines and accurate risk assessment. Patient compliance and persistence to available therapies is also necessary for successful modulation of CVD risk.
Introduction
Cardiovascular (CV) disease is the leading cause of disability and death in developed nations and is increasing in prevalence throughout the developing world (WHO 2002) . It also poses a huge economic burden; for example, in Sweden in 2005, CV disease (CVD) cost an estimated 48 billion SEK (US$7 billion), as measured in healthcare expenditures, medications, and lost productivity due to disability. The incidence of metabolic disease (including the metabolic syndrome and type 2 diabetes) is also increasing at an alarming rate in parallel with associated risk factors (Ford et al 2004) . This has led to an expansion in populations who are at increased risk of developing CVD at an earlier age.
Important advances in CVD and metabolic disease management have been facilitated by the identifi cation of a number of major risk factors, including hypertension, hyperlipidemia, insulin resistance, and obesity. Furthermore, studies determining the interrelated nature of risk factors have helped shape our approach to treatment. However, despite a large clinical evidence base, the implementation of strategies to prevent CVD and metabolic disease remain far from optimal. In this review data are presented underscoring the importance of an intensive global approach to risk management to reduce the clinical and economic burden, profi ling the most appropriate therapeutic interventions to achieve this.
Risk factors
Elevated blood pressure (BP), unfavorable levels of LDL and high density (HDL) cholesterol, cigarette smoking, obesity, physical inactivity, and diabetes are well established as major, modifi able CV risk factors (Hubert et al 1983) . A critically important characteristic of risk factors is that each has a continuous, progressive impact on total CV risk, with higher levels translating into greater risk (Greenland et al 2003) . Universal improvements in disease management and public health measures have led to an increasingly aging population in whom these risk factors have more time to cause vascular disease.
CV risk factors occur in clusters
Rather than existing in isolation, CV risk factors tend to occur as clusters (Mancia 2006) . For example, in a study determining the prevalence of CV disease risk factors among 14,690 Chinese adults aged 35-74 years, overall, 80.5%, 45.9%, and 17.2% of individuals had Ն1, Ն2, and Ն3 modifi able CVD risk factors (from dyslipidemia, hypertension, diabetes, cigarette smoking, or being overweight), respectively. In the US, the fi gures were 93.1%, 73.0%, and 35.9%, respectively (Gu et al 2005) . The metabolic syndrome is a particularly well-characterized example of co-existing CV and metabolic risk factors that is increasing in prevalence at an alarming rate (Elabbassi and Haddad 2005) . Several international organizations have published guidelines for diagnosis of the metabolic syndrome, and differences between guidelines highlight the debate surrounding the precise nature of the metabolic syndrome. In 2006, the International Diabetes Federation (IDF) produced an updated consensus on the defi nition of the metabolic syndrome which includes central obesity and two additional metabolic criteria (Table 1) .
As seen in Table 1 , metabolic syndrome is a condition, characterized by obesity, in which an individual has a cluster of risk factors that can lead to CVD. The clustering of key risk factors in metabolic syndrome is considered by some to be the result of insulin resistance (Daskalopoulou et al 2004) ; consequently, the syndrome also carries a greatly increased risk for the development of type 2 diabetes, which in turn increases CV risk even further (Zieve 2004 ). Typically, patients with metabolic syndrome will be older, obese, hypertensive (Csaszar et al 2006) , and have insulin resistance (McLaughlin et al 2003; Grundy 2006) . Global estimates of this condition are reported to be around 16% (Wild and Byrne 2005) ; although the situation in the United States is more advanced, where between 30%-40% of the population are reported to have metabolic syndrome (Cheung et al 2006; Ford 2005) .
Clinical relevance of risk factor clustering
The relationship between CV risk factors is synergistic, meaning that when multiple risk factors are present in a specifi c individual, each one is more important than if they were present in isolation (Greenland et al 2003) . Indeed, several studies have shown that a progressively greater number of additional CV risk factors is associated with a correspondingly poorer clinical outcome (Stamler et al 1993; Thomas et al 2001) .
The cumulative effect of modifi able risk factors was well illustrated in the INTERHEART study (Figure 1 ) (Yusuf et al 2004) . This standardized case-controlled study of acute myocardial infarction (MI) in 52 countries enrolled 15,152 cases and 14,820 controls. The relationship of smoking, history of hypertension or diabetes, waist: hip ratio, dietary patterns, physical activity, consumption of alcohol, blood apolipoproteins, and psychosocial factors to MI was demonstrated. The odds ratio (OR) for the association of these risk factors to MI and their respective population attributable risk (PAR) were calculated and the nine risk factors studied were reported to collectively represent more than 90% of the risk of an initial MI. In a similar analysis conducted by Baena Diez and colleagues (2002) , the association between increasing numbers of CV risk factors and the risk of suffering a major CV event was investigated in a study population of 2,248 patients. The results showed that the percentage of patients with 1, 2, 3, and 4-6 CV risk factors (from smoking, arterial hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes or obesity) was 32.8%, 17.5%, 6.9%, and 3.7%, respectively. The OR for experiencing a CV event associated to 1, 2, 3, and 4-6 CV risk factors was 1.6 (CI 95%: 0.9-2.7), 2.8 (CI 95%: 1.7-4.7), 3.6 (CI 95%: 1.9-6.5), and 5.6 (CI 95%: 2.9-10.8), respectively, again underlining the escalating risk associated with multiple risk factors. The mortality associated with the presence of additional CV risk factors in subjects with or without hypertension was analyzed in a study involving Ͼ80,000 male subjects (Thomas et al 2001) . The population was composed of 29,640 normotensive men without additional risk factors (reference group) and 60,343 men with hypertension with and without additional risk factors (familial history of diabetes; total cholesterol Ն250 mg/dL; heart rate Ͼ80 beats/min; current smoker; and body mass index [BMI] Ͼ28 kg/m 2 ). In patients aged Ͻ55 years with hypertension and one or two additional CV risk factors, CV mortality increased fi ve-fold in comparison with normotensive patients. The increased risk was even more apparent in patients who had more than two associated risk factors, where a 15-fold increase in CV risk was observed.
The clinical relevance of risk factor clustering is also well illustrated in patients with the metabolic syndrome. In a study of men aged between 42-60 years, the risk of CVD mortality over approximately 11 years increased at a considerably higher rate when they had metabolic syndrome (Figure 2 ) . Such patients are at considerable risk of developing atherosclerosis-related diseases, including a two-to four-fold increased risk of stroke and a three-to four-fold increased risk of MI compared with those without the metabolic syndrome Ninomiya et al 2004) . The metabolic syndrome also increases the risk of developing diabetes fi ve-to nine-fold (Hanson et al 2002; Laaksonen et al 2002) .
Implications for treatment Screening for risk factors
The synergistic relationship between individual CV risk factors should make the identifi cation and characterization of clusters a healthcare priority. If a patient presents with a particular risk factor, such as elevated BP, they should receive appropriate antihypertensive treatment; however, to establish total risk, a thorough patient assessment should be undertaken. Global risk assessment strategies have a number of benefi ts (Hackam and Anand 2003) . A major benefi t is that they raise awareness that CV risk is continuous and graded, and that it is related to the overall burden of risk. They also facilitate adjustment to take into account the severity of individual component risk factors. Furthermore, they emphasize that a more individualized treatment approach is required and reiterate that the clinician must not focus on one specifi c risk factor when multiple CV risk factors are present concomitantly (Hackam and Anand 2003) . Widely used risk assessment tools include the Framingham risk charts and the Systematic Coronary Risk Evaluation (SCORE) risk predicting system. It should be recognized that risk assessment tools should be used with a great amount of clinical judgment and the risk score should never be the only reason for treatment. Many factors that convey an increased risk are not included in the algorithms eg, abdominal obesity, low/high HDL, proteinuria, family history, exercise habits, food habits, and psychosocial factors. An individualized approach is therefore always needed to manage CV risk optimally.
The limitation of all risk scores is also that they only defi ne the CV risk over a limited period of time, usually 10 years. Furthermore, since global risk increases signifi cantly with age they underestimate the risk in young individuals over a life-long perspective. Consequently, in young subjects, even with a clustering of risk factors, the calculated global risk is not high enough to base treatment on a 'high-risk' concept. For those at a younger age it is probably easier for both the treating physician and the patient to visualize the risk as the 'relative risk increase' rather than the total risk. However, the fact that global risk will escalate with age alone is one that should not be ignored. Clearly, the communication of risk and risk-factor management in younger individuals is still a problem and current algorithms are left distinctly lacking in this respect. Figure 3 is based on the European Society of Cardiology (ESC) SCORE chart (Conroy et al 2003) and shows how age alone changes the 10-year risk if a patient with the same risk profi le is seen at different age brackets. It is also clear that young individuals are at lower risk even in the presence of signifi cant risk factors, and there is the potential for lowering risk if treatment is initiated earlier.
Multifactorial treatment approach to reduce CV events and the development of metabolic disease Treatment guidelines and society recommendations for the management of CVD and metabolic disease recognize that a Backer et al 2003) . Similarly, the IDF supports an aggressive, multifaceted treatment approach for individuals with metabolic syndrome (IDF 2006) . However, worldwide, physicians still tend to focus on managing a single CV risk factor, for example BP, rather than focusing on overall risk management (Volpe and Tocci 2006) . This situation must change if decreases in CV mortality and morbidity, and metabolic disease are to be achieved. Over recent years, data have emerged to quantify the benefi ts of a global approach. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) trial showed the benefi ts of combining antihypertensive and statin therapy (Sever et al 2003) . The primary objective of each of the two arms of ASCOT (BP lowering arm and lipid-lowering arm [LLA]) was to assess the differential effects on risk of nonfatal MI and fatal coronary heart disease (CHD) of two different treatment strategies assessed in a 2 × 2 factorial design. Following unblinding of the BP treatments in ASCOT-LLA, it was observed that the primary endpoint (nonfatal MI and fatal CHD) was signifi cantly reduced by 53% in the amlodipine/ atorvastatin group compared with amlodipine/placebo.
Similarly, in an analysis conducted by Athyros and colleagues (2005) , the effect of a multi-targeted treatment approach on CVD risk reduction in nondiabetic patients with metabolic syndrome was assessed. The study was a 12-month, randomized, open-label study, in which 300 nondiabetic patients with the metabolic syndrome and free of CVD at baseline, received lifestyle advice and a stepwiseimplemented drug treatment for hypertension, impaired fasting glucose and obesity. The patients were randomly allocated to three treatment groups for hypolipidemic treatment: atorvastatin (n = 100), micronized fenofi brate (n = 100), and both drugs (n = 100). At study end, lipid values were signifi cantly improved in all three treatment groups, with those treated with both atorvastatin and micronized fenofi brate attaining lipid targets to a greater extent than those in the other two groups. The study fi ndings support the concept that a target-driven and intensifi ed intervention aimed at multiple risk factors in nondiabetic patients with the metabolic syndrome substantially offsets its component factors, and signifi cantly reduces the estimated CVD risk (Athyros et al 2005) .
Individual risk factor management as part of a global approach
In order to prevent CV and metabolic diseases, each risk factor should be examined and treated appropriately within the context of a multifactorial approach (Table 2) . (Doll et al 1994) .
Lifestyle modifi cation

Obesity management
Obesity rates are increasing in epidemic proportions (Hedley et al 2004) . Abdominal obesity is particularly strongly associated with CV risk and has been shown to increase the risk of ischemic stroke by approximately three-fold (Suk et al 2003) . As well as being a signifi cant independent risk factor for CV disease, obesity is associated with an increased risk of developing other conditions associated . In this study, 56% of cases of diabetes were attributed to weight gain greater than 7 kg and 20% were attributed to a waist gain exceeding 2.5 cm. Whilst lifestyle modifi cation remains the major approach to the management of obesity, a number of anti-obesity drugs are available or in development and may have a role in reducing CV risk in obese or overweight patients (Table 2 ) (Klein 2004) .
A meta-analysis of clinical trials showed that sibutramine, orlistat and topiramate all reduced bodyweight in obese patients, while sibutramine was also associated with small improvements in HDL cholesterol (HDL-C) and very small improvements in glycemic control in patients with diabetes (Table 2 ) (Li et al 2005) .
As suggested for obesity, it is advocated that insulin resistance, as another underlying factor in the development of metabolic syndrome, is treated with lifestyle modifi cation as fi rst-line therapy in order to prevent the development of type 2 diabetes and reduce the risk of CV disease (Daskalopoulou 2004; Zieve 2004; Wagh and Stone 2004; Grundy 2005; Vitale 2006 ). However, when lifestyle modifi cation is no longer able to arrest the rise in blood glucose towards diabetic levels and clustering of risk factors progresses, intervention with drugs directed towards the individual risk factors is essential (Table 2 ) (Grundy 2006) .
BP lowering
Antihypertensive therapy to reduce BP is central to the management of CV risk and provides a starting point for initiating a more comprehensive CV risk management strategy (Chobanian 2003 Erhardt and Gotto 2006) . However, there is increasing evidence that even more aggressive BP targets may be warranted for patients at increased CV risk.
In a recent prospective cohort analysis among 8,960 middle-aged adults in the Atherosclerosis Risk in Communities (ARIC) study, individuals with prehypertensive levels of BP were found to have an increased risk of developing CVD relative to those with optimal levels (Kshirsagar et al 2006) . The association was found to be more pronounced among blacks, individuals with diabetes mellitus, and those with high BMI.
The ability to stratify patients according to their calculated total CV risk also questions whether high-risk patients, not classifi ed as hypertensive, should also receive antihypertensive therapy (Mancia 2006) . For example, a number of studies have shown that intensive BP lowering, even in patients whose baseline BP is Ͻ140/90 mmHg, is benefi cial in highrisk patients, including those with diabetes (Yusuf et al 2000; PROGRESS Collaboration Group 2001; Schrier et al 2002) . 
Dyslipidemia management
Several large, randomized, controlled trials have documented that cholesterol-lowering therapy with statins reduces the risk of death or CV events across a wide range of cholesterol levels, and that lipid management is integral to reducing CVD risk. In common with BP targets, lipid-lowering goals are also becoming more stringent. A recent analysis of the evolution of the Joint European Societies' guidelines with respect to their lipid recommendations stresses the importance of lowering lipid levels to, or below, the currently recommended goals (Table 2 ) (Erhardt 2006) . It was argued that the patients' global risk for CVD, rather than baseline lipid levels, should direct the intensity of lipid-lowering treatment.
There is evidence that more stringent targets than those currently recommended by international guidelines may result in greater reductions in CV risk. In the Heart Protection Study (HPS) -a landmark trial that looked at the effect of fi xed-dose statin (simvastatin 40 mg/day) by low-density lipoprotein cholesterol LDL-C subgroups (LDL-C Ͼ135; 116-135; and Ͻ116) -signifi cant LDL-C reductions were observed in each predefi ned LDL-C subgroup (LDL-C Ͼ135: 39%; LDL-C 116-135: 37%; and LDL-C Ͻ116: 35%) and these reductions correlated to comparable relative risk reductions (major vascular events: 19%, 26%, and 21%, respectively), irrespective of baseline LDL-C levels (Brown 2002) . Results from Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) in patients with acute coronary syndrome (Wiviott et al 2006) and Treating to New Targets (TNT) (LaRosa et al 2005) in patients with stable coronary artery disease, both showed that patients treated intensively to below target LDL levels experienced clinically signifi cant benefi ts in CV outcomes.
Additionally, the recently published results from A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) showed that intensive treatment with rosuvastatin resulted in a 53% reduction in LDL-C (from 130 mg/dL to 60.8 mg/dL) at 24 months and this was associated with signifi cant regression of atherosclerosis, supporting the benefi ts of intensive lipid lowering (Nissen et al 2006) .
Prevention of new-onset diabetes
Oral antidiabetic agents may provide a means to treat impaired glucose tolerance (IGT) and delay new-onset diabetes in patients with or without the metabolic syndrome ( Table 2 ). In the Diabetes Prevention Program (DPP), treatment with metformin reduced the risk of developing type 2 diabetes by 31%, compared with placebo, in patients with prediabetes (Kitabchi et al 2005) . However, this reduction was smaller than that achieved with intensive lifestyle modification (58%). Recent thiazolidinedione studies have also demonstrated effi cacy in delaying or preventing type 2 diabetes in patients with IGT and insulin resistance (Buchanan et al 2002; Knowler et al 2002) . Other studies have shown that both acarbose and orlistat can be used to delay the development of type 2 diabetes in patients with IGT (Chiasson et al 2003; Torgerson et al 2004) . In addition, the Diabetes REduction Assessment with rAmipril and rosiglitazone Medication (DREAM) (ramipril and rosiglitazone) study which enrolled 5,269 adults with impaired fasting glucose (IFG) or IGT, showed that rosiglitazone reduced the risk of new type 2 diabetes by 60% (DREAM Trial Investigators 2006a) . In contrast, although ramipril resulted in a signifi cant number of patients achieving normoglycemia (p = 0.001 vs placebo), it did not signifi cantly reduce the risk of developing type 2 diabetes (DREAM Trial Investigators 2006b) .
In addition to the benefi ts of BP reduction per se, there is strong evidence that angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are associated with a reduction in the risk of newonset diabetes (Table 2) (McCall et al 2006) . However, recent data from the DREAM study showed that although the ACE-I ramipril modestly improved glycemic status in patients with IFG or IGT; it had no signifi cant effect on the risk of new type 2 diabetes (DREAM Trial Investigators 2006b). More favorable results have been reported from studies of ARBs such as the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study, in which the ARB valsartan was found to reduce the risk of new-onset diabetes by 23% compared with the calcium channel blocker amlodipine in patients with hypertension and at high risk of cardiac events (Julius et al 2004) . Similarly, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, patients with hypertension and left ventricular hypertrophy who received the ARB losartan had a 25% reduction in new-onset diabetes compared with patients receiving the β-blocker atenolol (Dahlöf et al 2002) . Candesartan was also found to reduce the risk of new-onset diabetes by 25% in elderly patients with hypertension in the Study on Cognition and Prognosis in the Elderly (SCOPE) (Lithell et al 2003) and by 40% in patients with congestive heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM)-preserved study (Yusuf et al 2003) . In addition, the Antihypertensive treatment and Lipid Profi le In a North of Sweden Effi cacy Evaluation (ALPINE) study showed that candesartan was associated with new diagnoses of type 2 diabetes in only one of 197 patients, compared with eight of 196 patients receiving hydrochlorothiazide (Lindholm et al 2003) .
Currently, there is little or no evidence that preventing diabetes will translate into subsequent prevention of CV events. As such, it remains unproven that patients would benefi t from diabetes prevention in terms of reductions in CV events. The ongoing Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVI-GATOR) trial in patients with IGT and CVD or at CV risk, the largest diabetes trial with an ARB conducted to date, is the only diabetes prevention study also powered to show a reduction in CVD and will provide important information on this topic.
Management issues Awareness and detection of risk factors
Effective management of CV risk and metabolic disease through intensive treatment of multiple risk factors must overcome several key obstacles. Firstly, the risk factors need to be detected earlier and quantifi ed. Rates of detection and treatment of CV risk factors are low. For example, as part of the Multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) study, it was found that in Northern Sweden, only 50% of individuals with hypertension received treatment and the majority of these patients were uncontrolled (Jansson et al 2003) . Europe-wide data from MONICA showed that awareness of hypercholesterolemia varied considerably between populations, with 3%-62% of men and 0%-65% of women being aware of their elevated cholesterol (Tolonen et al 2005) . Low levels of awareness result in low levels of treatment: in the MONICA study only 45% of men and 44% of women were receiving treatment for their hypercholesterolemia. Public health education plays an integral part in raising awareness about CV risk factors.
Improved screening for CV risk factors and the metabolic syndrome is vital if long-term reductions in overall morbidity and mortality are to be achieved. Many CV risk factors (such as hypertension, hypercholesterolemia, or IGT) are 'silent' and individuals will not necessarily be aware that they are at an increased risk. Reducing overall CV risk therefore needs to begin by evaluating all known modifi able risk factors so that a detailed CV and metabolic risk-status profi le can be created and appropriate management implemented. Secondly, while many individuals recognize that their behavior is associated with increased CV risk, there is often a lack of motivation to make lifestyle changes. Strategies such as motivational interviewing (Shinitzky and Kub 2001) and improving community opportunities for physical activity can be effective at helping patients to implement and maintain lifestyle changes. Thirdly, physicians need to recognize the importance of early and aggressive treatment and make appropriate therapeutic interventions based on current guidelines and accurate risk assessment. However, physicians' assessments of CV risk may deviate signifi cantly from scores measured using the risk charts, suggesting that initiatives are needed to promote accurate risk assessment techniques (Mosca et al 2005) . Generally, primary care physicians seem to underestimate total CV risk (Figure 4) , thus making the use of tools to assess the CV risk important in clinical practice (Backlund et al 2004) .
Future algorithms need to be able to assess lifetime risk and guide the clinician toward optimal treatment, even if, as in younger individuals, the 10-year risk of CV events is not excessively high.
Compliance and persistence
Once pharmacological interventions have been prescribed, patients need to exhibit a high level of compliance and persistence in order to derive optimal benefi t from the therapy. It has been estimated that poor therapeutic compliance contributes to lack of BP control in over two-thirds of patients with hypertension, while up to half of patients receiving antihypertensive drugs discontinue treatment within 6 months to 4 years (Anonymous 2005) . This lack of compliance can invariably lead to increased resource utilization, which in turn, will lead to increased economic burden ( Figure 5 ) (Goldman et al 2006) . Improved compliance to medication signifi cantly reduces this burden. Prescription patterns among primary care physicians have been shown to infl uence discontinuation of medication and general practitioners with high levels of prescribing attain higher rates of early discontinuation compared with colleagues with low levels of prescribing (Hansen at al 2007) . Strategies that have been shown to improve compliance and persistence include the use of drugs with convenient dosing regimens and better tolerability profi les, however, the importance of adherence still needs to be reinforced by governmental and health agencies.
Conclusions
Cardiovascular disease and metabolic disease are characterized by multiple concurrent and interrelated causes. Many risk factors for CVD can be treated effectively with existing, well-tolerated pharmacotherapies. There is now convincing evidence of the need for an early, intensive, and integrated approach to the management of multiple risk factors for CV disease to reduce the long-term clinical burden. Riskfactor screening, recognition of risk factor clustering and an integrated approach to multiple risk management, together with government and health agency driven public education, should result in reductions in total CV and metabolic risk, with concurrent clinical and economic benefi ts.
